Transdermal lisuride delivery in the treatment of Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 68, 2004, Pages 89-95

  Woitalla, D ^a   Muller T ^a   Benz, S ^a   Horowski, R ^b   Przuntek, H ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b NeuroBiotec Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SELF REPORT; SKIN EDEMA; SKIN IRRITATION; TRANSDERMAL PATCH;

EID: 4544326052     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0579-5_10     Document Type: Article

References (18)

1. Baas H, Harder S, Demisch L, Burklin F, Stecker K, Fischer PA (1995) Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics. J Neural Transm [Suppl] 46: 367-379
2. Behrens S, Sommerville K (2003) Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders, 10-14 November 2002, Miami, FL, USA. Expert Opin Pharmacother 4: 595-599
3. Bennett JP Jr, Turk M, Landow E (1989) Continuous oral administration of L-dihydroxyphenylalanine (L-DOPA) solution to patients with advanced Parkinson's disease. Clin Neuropharmacol 12: 285-292
4. Calabrese VP, Vaughan J, Lucas J, Hong AQ, Barrett R, Martin P, Sica D (1997) N-0923, a transdermal amino tetralin D2 dopamine agonist in the treatment of Parkinson's disease. Neurology 48: 32005
5. Danhof M, van der Geest R, van Laar T, Bodde HE (1998) An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease. Adv Drug Delivery Rev 33: 253-263
6. Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41: 261-309
7. Fahn S, Elton R, Members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. Macmillan, New York, pp 153-163
8. Hoehn MM, Yahr MD (2001) Parkinsonism: onset, progression, and mortality. 1967. Neurology 57: S11-S26
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]. J Neurol Neurosurg Psychiatry 55: 181-184
10. Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, Lewitt PA, Samii A, Tsui JKC, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL (2001) Transdermal dopaminergic D-2 receptor agonist therapy in parkinson's disease with n-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 16: 459-463
11. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN (2001) Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 24: 163-169
12. Montastruc JL, Ziegler M, Rascol O, Malbezin M (1999) A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. Mov Disord 14: 336-341
13. Müller T (2002) Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 3: 1393-1403
14. Pfeiffer RF (2002) Potential of transdermal drug delivery in Parkinson's disease. Drugs & Aging 19: 561-570
15. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105: 245-255
16. Rinne UK (1999) [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy]. Nervenarzt 70 [Suppl 1]: S19-S25
17. Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RKB, Jenner P (2000) Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol 23: 133-142
18. Sudo J, Iwase H, Terui J, Kakuno K, Soyama M, Takayama K, Nagai T (1998) Transdermal absorption of L-dopa from hydrogel in rats. Eur J Pharmaceut Sci 7: 67-71